What Danaher (DHR)'s New p-Tau217 Alzheimer’s Assays Mean For Shareholders

Simply Wall St.07-08

Danaher’s Beckman Coulter Diagnostics unit has secured a CE Mark under IVDR for its Access p-Tau217 blood assay and introduced a high-specificity BD-pTau217 research-use-only test, both now available ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649030961?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-07-08 16:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649030961","market":"hk","top_or_hot":-1,"title":"What Danaher (DHR)'s New p-Tau217 Alzheimer’s Assays Mean For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Danaher’s Beckman Coulter Diagnostics unit has secured a CE Mark under IVDR for its Access p-Tau217 blood assay and introduced a high-specificity BD-pTau217 research-use-only test, both now available ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/what-danaher-dhrs-new-p-tau217-alzheimers-assays-mean-for-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Danaher (DHR)'s New p-Tau217 Alzheimer’s Assays Mean For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Danaher (DHR)'s New p-Tau217 Alzheimer’s Assays Mean For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/what-danaher-dhrs-new-p-tau217-alzheimers-assays-mean-for-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Danaher’s Beckman Coulter Diagnostics unit has secured a CE Mark under IVDR for its Access p-Tau217 blood assay and introduced a high-specificity BD-pTau217 research-use-only test, both now available ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/what-danaher-dhrs-new-p-tau217-alzheimers-assays-mean-for-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004303.SGD","symbol_name":"Nikko AM Shenton Global Opportunities SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/what-danaher-dhrs-new-p-tau217-alzheimers-assays-mean-for-sh","article_id":"2649030961","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/what-danaher-dhrs-new-p-tau217-alzheimers-assays-mean-for-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649030961","pubTimestamp":1783499263,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Danaher’s Beckman Coulter Diagnostics unit has secured a CE Mark under IVDR for its Access p-Tau217 blood assay and introduced a high-specificity BD-pTau217 research-use-only test, both now available on the DxI 9000 Immunoassay Analyzer to support evaluation of amyloid pathology in patients with cognitive decline.\nThis push into blood-based Alzheimer’s-related diagnostics strengthens Danaher’s higher-margin, innovation-led diagnostics portfolio, potentially deepening its recurring...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","DHR":"丹纳赫","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","FMED":"Fidelity Disruptive Medicine ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","DHR.AU":"Dark Horse Resources","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4504":"桥水持仓","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4588":"碎股","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2"},"translate_title":"丹纳赫(DHR)的新型p-Tau217阿尔茨海默病检测对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1.5,"FMED":0.6,"DHR.AU":1.5},"content_text":"Danaher’s Beckman Coulter Diagnostics unit has secured a CE Mark under IVDR for its Access p-Tau217 blood assay and introduced a high-specificity BD-pTau217 research-use-only test, both now available on the DxI 9000 Immunoassay Analyzer to support evaluation of amyloid pathology in patients with cognitive decline. This push into blood-based Alzheimer’s-related diagnostics strengthens Danaher’s higher-margin, innovation-led diagnostics portfolio, potentially deepening its recurring consumables and services footprint within hospital and reference laboratory workflows. We’ll now examine how Beckman Coulter’s CE-marked p-Tau217 assay and expanded DxI 9000 menu could influence Danaher’s investment narrative. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AdvertisementDanaher Investment Narrative RecapTo own Danaher, you need to believe in its ability to compound value from recurring, innovation-led diagnostics and life sciences platforms, even as growth expectations are already reflected in a relatively rich earnings multiple. The new p-Tau217 blood assay strengthens the diagnostics story but is unlikely to shift near term focus from the key catalyst of broader menu adoption across its installed base, or the important risk that higher innovation spending could pressure margins if uptake disappoints. The most relevant recent development here is Beckman Coulter’s CE-marked Access p-Tau217 assay on the DxI 9000 Immunoassay Analyzer, which adds a clinically important, high-complexity test to a single high-throughput platform. That fits with the broader catalyst of expanding high-margin consumables and services tied to Danaher’s large analyzer footprint, even as investors monitor whether rising operating costs tied to these launches are matched by sustainable volume growth. But while this kind of innovation can be attractive, investors should also be aware of the risk that... Read the full narrative on Danaher (it's free!)Danaher’s narrative projects $31.2 billion revenue and $6.5 billion earnings by 2029.Uncover how Danaher's forecasts yield a $242.35 fair value, a 25% upside to its current price.Exploring Other PerspectivesDHR 1-Year Stock Price Chart Five members of the Simply Wall St Community value Danaher between US$187 and about US$258.95 per share, showing a wide spread of expectations. When you set these opinions against the growing weight on high margin diagnostics and the risk that innovation spending may not fully translate into profitable volume, it underlines why you may want to compare several viewpoints before forming your own stance.Explore 5 other fair value estimates on Danaher - why the stock might be worth just $187.00!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Danaher research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Danaher research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Danaher's overall financial health at a glance.Looking For Alternative Opportunities?Opportunities like this don't last. These are today's most promising picks. Check them out now:Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649030961","isCrawlerRequest":true}